Galactagogue Use in Lactating Women With Low Milk Supply
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Galactagogue Supplement for Treatment of Low Milk Supply.
- Who it may be relevant to
- Registry conditions: Breast Milk Expression. Basic parameters: 18 years — 40 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effect of Single Ingredient and Blend Galactagogue Supplements on Increasing Milk Supply in Lactating Women Experiencing Diagnosed or Perceived Low Milk Supply
Overview
This study aims to determine whether a 20-day supplement with either Oat Mama Lactation Supplement, moringa, or shatavari has any impact on milk production through an increase in serum prolactin levels when compared to the placebo group. This data will be used to determine if clinical recommendations can be made for the use of the studied supplements in increasing milk supply.
Detailed description
This study will be a double-blind randomized control trial where eligible participants will be randomized into one of four treatment groups: Oat Mama Lactation Supplement (O), moringa supplement (M), shatavari supplement (S), or control (C). All participants will receive a supplement or placebo for consumption throughout the 20-day trial period, and all participants will receive support from a lactation consultant once per week to receive appropriate guidance for increasing milk supply. 24-hour milk output will be recorded on day 1, 10, and 20 using either pre- and post-feeding weights, 24-hour pump output, or a combination of both. Additionally, blood samples will be taken on day 1, 10, and 20 and serum will be isolated for later analysis of serum prolactin levels.
Interventions
- Dietary supplement Galactagogue Supplement for Treatment of Low Milk Supply
Participants will consume a commercially available dietary supplement on the market for augmentation of breast milk production in lactating women with low milk supply
Primary outcome measures
- Change in Breast Milk Supply [Time frame: Intervention will last 20 days and 24-hour breast milk expression volume will be measured on day 1, 10, and 20 and used to calculate change in 24-hour breast milk expression volume over the trial period]
- Change in Serum Prolactin [Time frame: Intervention will last 20 days and blood samples will be taken on day 1, 10, am 20 and change in serum prolactin will be measured using a human serum prolactin ELISA kit]
Eligibility criteria
Inclusion Criteria: Participants in the study must:
- Be struggling with diagnosed or perceived low milk supply
- Be willing to consume a randomly assigned galactagogue or placebo supplement
- Be willing to provide a blood sample at each lactation consult (day 1, 10, 20)
- Be willing to provide 24-hour expressed milk volume either using pre- and post-feed weights, total pump output, or a combination of both on day 1, 10, and 20
Exclusion Criteria: Participants will be excluded if:
- They have a history of breast reduction
- They have a history of utilizing in vitro fertilization
- They are not a biological female with mammary glands present for producing milk
- They have consumed galactagogues with the intention of increasing their milk supply during the current lactation cycle
- They are under age 18 or above age 39
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Winthrop University — Rock Hill
Identifiers
NCT: NCT05398367 · IRB22107R